BioArctic AB
- Company typePublic
- Founded2003
- HeadquartersStockholm, Sweden
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
BioArctic AB firmographics
Firmographics- Name
- BioArctic AB
- Legal name
- BioArctic AB
- Website
- https://bioarctic.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
BioArctic AB industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where BioArctic AB is headquartered
LocationHeadquarters
- HQ city
- Stockholm
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
BioArctic AB business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Leqembi Royalties: BioArctic receives tiered royalties on global sales of Leqembi from its long-standing partnership with Eisai (dating back to 2005). Royalty income has been growing significantly, reaching SEK 160.8 million in Q1 2026 (+68% YoY). Leqembi is approved in 53 countries with regulatory review ongoing in 6 more.
- Milestone Payments: BioArctic receives milestone payments upon achievement of regulatory and sales milestones from partners. In Q1 2026, a EUR 20 million milestone was triggered when Leqembi global sales exceeded EUR 500 million. Additional milestones are tied to subcutaneous formulation approvals and sales targets.
- Upfront and Milestone Payments from BrainTransporter Licensing: BioArctic receives upfront payments, milestone payments, and tiered royalties from licensing its BrainTransporter technology to pharmaceutical partners. Deal with Eli Lilly: $30M upfront + up to $770M milestones + mid-single-digit royalties. Deal with Novartis: $30M upfront + up to $772M milestones + mid-single-digit royalties. Deal with Bristol Myers Squibb: $100M upfront + up to $1.25B milestones + tiered low double-digit royalties.
- Nordic Co-commercialization: BioArctic retains rights to co-commercialize Leqembi in the Nordic region alongside Eisai, generating revenue from direct product sales in Sweden, Norway, Finland, and Denmark.
Go-to-market motion1 record
Distribution channels5 records
Marketing channels5 records
BioArctic AB product offering
Product offeringCore offering
BioArctic AB is a Swedish research-based biopharma company developing antibody treatments for neurodegenerative diseases (primarily Alzheimer's and Parkinson's). Its flagship product is Leqembi (lecanemab), an amyloid-beta oligomer/protofibril antibody co-developed and globally commercialized by partner Eisai as the first proven disease-modifying treatment for early Alzheimer's disease. The company also licenses its proprietary BrainTransporter technology platform, a transferrin receptor-based system that ferries biologic drugs across the blood-brain barrier, to partners including Bristol Myers Squibb, Novartis, and Eli Lilly.
Product overview
BioArctic AB is a Swedish research-oriented biopharma company focused on innovative treatments for neurodegenerative diseases. The core product is Leqembi (lecanemab), the world's first proven disease-modifying drug for early Alzheimer's disease, developed with partner Eisai. Leqembi works by targeting harmful amyloid-beta oligomers and protofibrils. The company is expanding its formulation options with Leqembi Iqlik, a weekly subcutaneous autoinjector under regulatory review. BioArctic's proprietary BrainTransporter technology platform facilitates active transport of antibodies across the blood-brain barrier using the transferrin receptor, enhancing drug efficacy and enabling improved dosing. The pipeline includes exidavnemab for Parkinson's disease and Multiple System Atrophy (Phase 2a), plus licensed programs BAN1503 and BAN2803 for PyroGlutamate-amyloid-beta targeting (with Bristol Myers Squibb) and BAN2238 for alpha-synuclein in Parkinson's. The research portfolio spans Alzheimer's disease, Parkinson's disease, and ALS, with several projects utilizing the BrainTransporter platform either internally or through external partnerships (Eisai, Bristol Myers Squibb, Novartis, Eli Lilly).
Differentiator
Problem solved
Functional benefit
Brands
- Leqembi (lecanemab): World's first drug proven to slow the progression of Alzheimer's disease and reduce cognitive impairment in early Alzheimer's disease. Developed in partnership with Eisai.
- BrainTransporter
- Leqembi Iqlik
Products and services
- Leqembi (lecanemab) Leqembi (lecanemab) is a humanized monoclonal antibody that selectively binds to and clears the most toxic forms of amyloid-beta — soluble protofibrils and insoluble fibrils — for the treatment of early Alzheimer's disease (mild cognitive impairment and mild Alzheimer's dementia). It is the first disease-modifying treatment for early Alzheimer's disease, co-developed with Eisai and globally commercialized by Eisai (with BioArctic co-promoting in the Nordic region).
- BrainTransporter technology BrainTransporter is BioArctic's proprietary, patented drug-delivery technology that uses transferrin receptor-mediated active transport to ferry biologic drugs across the blood-brain barrier. It is licensed to pharma partners (Bristol Myers Squibb, Novartis, Eli Lilly) on a standalone basis to be incorporated into partners' antibody and biologic candidates, reducing the required drug dose, expanding brain exposure, and enabling less frequent dosing. It is sold via licensing, collaboration, and option-to-acquire agreements generating upfront payments, R&D funding, milestone payments, and tiered royalties.
Quantifiable outcome
- 31% reduction in clinical decline on CDR-SB cognitive scale at 18 months (Phase 3 Clarity AD trial, in ApoE ε4 non-carriers or heterozygotes)
- +6 more outcomes
Companies that use BioArctic AB
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles1 record
BioArctic AB technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
BioArctic AB partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Eli Lilly and CompanycoreResearch and collaboration agreement to develop a potential neurodegeneration treatment combining BioArctic's BrainTransporter technology with an undisclosed Lilly drug candidate. BioArctic receives $30 million upfront, up to $770 million in milestone payments, and tiered mid-single-digit royalties on future global product sales. Lilly assumes full responsibility for global development and commercialization. This is BioArctic's fourth BrainTransporter collaboration.
- Novartis Pharma AGcoreOption, collaboration and license agreement using BrainTransporter technology for a neurodegeneration target. BioArctic received $30 million upfront. If Novartis exercises its option after evaluating initial research results, BioArctic is eligible for additional payments up to $772 million plus tiered mid-single-digit royalties. Novartis assumes responsibility for global development and commercialization if option is exercised. This is BioArctic's third BrainTransporter collaboration.
- Bristol Myers SquibbcoreGlobal exclusive license agreement for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803 (the latter includes BrainTransporter technology). BioArctic received $100 million upfront and is eligible for up to $1.25 billion in milestone payments plus tiered low double-digit royalties on global product sales. Bristol Myers Squibb assumes sole responsibility for global development and commercialization. BioArctic retains option to co-commercialize in the Nordic region.
- Eisai Co., Ltd.coreLong-standing collaboration dating back to 2005 for the development and commercialization of Leqembi (lecanemab). BioArctic invented Leqembi and co-developed it with Eisai. Eisai is responsible for global clinical development, regulatory interactions, and commercialization, while BioArctic receives milestone payments and tiered royalties on global sales. BioArctic retains co-commercialization rights in the Nordic region. Eisai has also entered a research evaluation agreement regarding BAN2802 using the BrainTransporter technology.
- Biogen Inc.coreBiogen co-developed and co-commercializes Leqembi (lecanemab) with Eisai. BioArctic is the original inventor of Leqembi and works with Eisai as primary partner, with Biogen involved as co-commercialization partner with Eisai for the product.
- Uppsala UniversitycoreBioArctic's Leqembi was originally developed based on research from Uppsala University led by Professor Lars Lannfelt on the Arctic mutation in Alzheimer's disease. The company maintains academic roots in Swedish research and co-founder Professor Lars Lannfelt continues to contribute to the company's scientific advisory.
Scale indicators12 records
Recent moves6 records
Expansion highlights5 records
BioArctic AB competitors and assessment
Company assessmentBroad incumbents
- Eli Lilly and Company: Major pharma developing Kisunla (donanemab) for early Alzheimer's disease and a BrainTransporter collaboration partner with BioArctic. Directly competes in the anti-amyloid Alzheimer's space and validates the BrainTransporter platform via the 2026 collaboration.
- Roche / Genentech: Major incumbent pharma with multiple Alzheimer's programs (gantenerumab history and ongoing CNS pipeline). Competes indirectly with Leqembi and is a potential future BrainTransporter or neurodegeneration partner for BioArctic.
- Novartis AG: Major pharma with active neurodegeneration R&D and a recent BrainTransporter option/license partner with BioArctic. Overlaps with BioArctic on CNS pipeline and validates the platform while posing broader competition in adjacent neurodegenerative indications.
- Bristol Myers Squibb: Major pharma that took an exclusive license to BioArctic's PyroGlu-Aβ program (BAN1503/BAN2803) for up to $1.35B. Both a key BioArctic partner and a broader neurodegenerative disease competitor via its large pharma pipeline.
Direct peers
- Eisai Co., Ltd. Long-standing BioArctic partner for Leqembi (lecanemab) since 2005 and global commercialization lead. Operates in the same neurodegenerative disease space as BioArctic and is effectively a co-developer of Leqembi, sharing the same disease-modifying Alzheimer's thesis.
- Biogen Inc. Co-commercialization partner with Eisai for Leqembi and historical developer of Aduhelm. Active in the same disease-modifying Alzheimer's space and shares commercial economics on BioArctic's flagship product.
- Denali Therapeutics: Clinical-stage biotech developing a transferrin receptor (TfR)-based blood-brain barrier delivery platform (ATV) plus neurodegenerative disease antibodies. Most direct technology peer to BioArctic's BrainTransporter franchise.
- Prothena Corporation: Clinical-stage biotech with a pipeline of antibody therapeutics for neurodegenerative diseases including Parkinson's (alpha-synuclein) and Alzheimer's. Comparable pipeline-stage biotech with similar CNS biologics strategy.
Emerging players
- AC Immune SA: Swiss clinical-stage biopharma developing anti-amyloid and tau-targeting therapeutics for Alzheimer's and other neurodegenerative diseases. Competes for partnership and capital in the same disease-modifying AD pipeline space.
- Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease. Competes for investor attention and partnership interest in the disease-modifying Alzheimer's space alongside BioArctic's Leqembi franchise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
BioArctic AB social profiles
Digital presenceBioArctic AB compliance and trust
Trust signalCompliance2 records
BioArctic AB financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioArctic AB leadership team
Management profileNumber of profiles
Profiles6 records
BioArctic AB funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioArctic AB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioArctic AB
What does BioArctic AB do?
BioArctic AB is a Swedish research-based biopharma company developing antibody treatments for neurodegenerative diseases (primarily Alzheimer's and Parkinson's). Its flagship product is Leqembi (lecanemab), an amyloid-beta oligomer/protofibril antibody co-developed and globally commercialized by partner Eisai as the first proven disease-modifying treatment for early Alzheimer's disease. The company also licenses its proprietary BrainTransporter technology platform, a transferrin receptor-based system that ferries biologic drugs across the blood-brain barrier, to partners including Bristol Myers Squibb, Novartis, and Eli Lilly.
Is BioArctic AB a public or private company?
BioArctic AB is a public company. It is classified as public and is currently operating.
When was BioArctic AB founded?
BioArctic AB was founded in 2003. It employs 101 to 250 people.
Where is BioArctic AB based?
BioArctic AB is headquartered in Stockholm, Sweden, in the Europe region.
How does BioArctic AB make money?
Four revenue lines are on record. Leqembi Royalties are the primary driver. The others are milestone Payments, upfront and Milestone Payments from BrainTransporter Licensing and nordic Co-commercialization.
Who are BioArctic AB's main competitors?
Broad incumbents on record are Eli Lilly and Company, Roche / Genentech, Novartis AG and Bristol Myers Squibb. Direct peers are Eisai Co., Ltd., Biogen Inc., Denali Therapeutics and Prothena Corporation. Emerging players are AC Immune SA and Cassava Sciences.
Does BioArctic AB have an API?
No public API is recorded for BioArctic AB.
What industry is BioArctic AB in?
BioArctic AB's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.